articleThe Lancet Infectious DiseasesOct 12, 2020Closed access

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

MBMatteo BassettiRERoger EcholsYMYuko MatsunagaMAMari AriyasuYDYohei Doi

Ospedale Policlinico San Martino · University of Genoa · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

774
total citations
FWCI
29.89
Percentile
100%
References
29
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • Medicine
  • Pneumonia
  • Clinical endpoint
  • Carbapenem
  • Population
  • Sepsis
  • Antibiotics
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding